BRPI0607416A2 - composição farmacêutica compreendendo uma combinação de agentes parasimpatolìtico, simpatomimético e anestésico local, e uso da mesma na preparação de medicamento - Google Patents

composição farmacêutica compreendendo uma combinação de agentes parasimpatolìtico, simpatomimético e anestésico local, e uso da mesma na preparação de medicamento

Info

Publication number
BRPI0607416A2
BRPI0607416A2 BRPI0607416-2A BRPI0607416A BRPI0607416A2 BR PI0607416 A2 BRPI0607416 A2 BR PI0607416A2 BR PI0607416 A BRPI0607416 A BR PI0607416A BR PI0607416 A2 BRPI0607416 A2 BR PI0607416A2
Authority
BR
Brazil
Prior art keywords
combination
pharmaceutical composition
local anesthetic
preparation
parasympatholytic
Prior art date
Application number
BRPI0607416-2A
Other languages
English (en)
Inventor
Walid Khatib
Original Assignee
Thea Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thea Lab filed Critical Thea Lab
Publication of BRPI0607416A2 publication Critical patent/BRPI0607416A2/pt
Publication of BRPI0607416B1 publication Critical patent/BRPI0607416B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

COMPOSIçãO FARMACêUTICA COMPREENDENDO UMA COMBINAçãO DE AGENTES PARASIMPATOLìTICO, SIMPATOMIMéTICO E ANESTéSICO LOCAL, E USO DA MESMA NA PREPARAçãO DE MEDICAMENTO. A invenção se refere a uma composição farmacêutica caracterizada em que contém uma combinação de um agente parasimpatolítico, um agente simpatomimético, e um anestésico local. Tal composição pode ser injetada na câmara anterior do olho antes de uma operação de catarata, ou instilada no olho antes do tratamento com laser.
BRPI0607416-2A 2005-03-09 2006-03-09 Composição farmacêutica para administração intracameral compreendendo uma combinação de agentes parasimpatolítico, simpatomimético e anestésico local, e uso da mesma na preparação de medicamento BRPI0607416B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0502357A FR2882930B1 (fr) 2005-03-09 2005-03-09 Nouvelles compositions ophtalmologiques et leur mode d'utilisation
FR0502357 2005-03-09
PCT/FR2006/000528 WO2006095095A1 (fr) 2005-03-09 2006-03-09 Compositions ophtalmologiques et leur mode d’utilisation

Publications (2)

Publication Number Publication Date
BRPI0607416A2 true BRPI0607416A2 (pt) 2009-09-08
BRPI0607416B1 BRPI0607416B1 (pt) 2023-06-06

Family

ID=

Also Published As

Publication number Publication date
EP1858481B1 (fr) 2019-05-08
LT1858481T (lt) 2019-07-10
FR2882930B1 (fr) 2009-03-27
HRP20191044T1 (hr) 2019-09-06
LTPA2019017I1 (lt) 2019-12-10
CA2598503C (fr) 2014-01-28
NL301017I2 (nl) 2020-04-30
WO2006095095A1 (fr) 2006-09-14
US20120220637A1 (en) 2012-08-30
PL1858481T3 (pl) 2019-09-30
NO20074850L (no) 2007-09-24
NO2017008I2 (no) 2017-03-24
TR201908487T4 (tr) 2019-07-22
JP2008532985A (ja) 2008-08-21
LUC00136I2 (pt) 2021-02-12
CN101151018A (zh) 2008-03-26
US20080194649A1 (en) 2008-08-14
CA2598503A1 (fr) 2006-09-14
LUC00136I1 (pt) 2019-11-04
NL301017I1 (nl) 2019-11-06
CY2019042I2 (el) 2020-05-29
FR2882930A1 (fr) 2006-09-15
NO2017008I1 (no) 2017-03-24
CY1121865T1 (el) 2020-05-29
TNSN07343A1 (fr) 2008-12-31
ES2728071T3 (es) 2019-10-22
KR20070111501A (ko) 2007-11-21
MA29269B1 (fr) 2008-02-01
MX2007010295A (es) 2007-12-11
US9289399B2 (en) 2016-03-22
SI1858481T1 (sl) 2019-08-30
NO339793B1 (no) 2017-01-30
HUE043668T2 (hu) 2019-08-28
IL185197A0 (en) 2008-01-06
EP1858481A1 (fr) 2007-11-28
RU2007137115A (ru) 2009-04-20
PT1858481T (pt) 2019-06-14
CY2019042I1 (el) 2020-05-29
DK1858481T3 (da) 2019-06-03
RU2392925C2 (ru) 2010-06-27

Similar Documents

Publication Publication Date Title
NO20074850L (no) Oftalmologiske sammensetninger og anvendelse derav
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR048324A1 (es) Metodos para tratar infecciones por vih
BRPI0510778B8 (pt) composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR062860A1 (es) Combinaciones terapeuticas 482
BR112012033077B8 (pt) Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
AR048333A1 (es) Metodos de tratamiento de infeccion de vih
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BRPI0716765A8 (pt) Métodos e composições para administrar agentes hipoglicêmicos de longa duração
BR112012009857A2 (pt) composições farmacêuticas sólidas contendo um inibidor de integrase
PA8542701A1 (es) Composición parenteral reconstituible
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
BRPI0514724A (pt) inibidores da enzima hiv integrase
BRPI0409742A (pt) uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2468 DE 24/04/2018 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/03/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.